---
document_datetime: 2025-12-02 06:39:42
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/zyprexa-velotab.html
document_name: zyprexa-velotab.html
version: success
processing_time: 0.1117003
conversion_datetime: 2025-12-25 12:51:18.868942
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Zyprexa Velotab

[RSS](/en/individual-human-medicine.xml/67055)

##### Authorised

This medicine is authorised for use in the European Union

olanzapine Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Zyprexa Velotab. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Zyprexa Velotab.

Expand section

Collapse section

## What is Zyprexa Velotab?

Zyprexa Velotab is a medicine that contains the active substance olanzapine. It is available as yellow, round 'orodispersible' tablets (5, 10, 15 and 20 mg). Orodispersible tablets are tablets that dissolve in the mouth.

## What is Zyprexa Velotab used for?

Zyprexa Velotab is used to treat adults with schizophrenia. Schizophrenia is a mental illness that has a number of symptoms, including disorganised thinking and speech, hallucinations (hearing or seeing things that are not there), suspiciousness and delusions (mistaken beliefs). Zyprexa Velotab is also effective in maintaining improvement in patients who have responded to an initial course of treatment.

Zyprexa Velotab is also used to treat moderate to severe manic episodes (extremely high mood) in adults. It can also be used to prevent the recurrence of these episodes (when symptoms come back) in adults with bipolar disorder (a mental illness causing alternating periods of high mood and depression) who have responded to an initial course of treatment.

The medicine can only be obtained with a prescription.

## How is Zyprexa Velotab used?

The recommended starting dose of Zyprexa Velotab depends on the disease being treated: 10 mg per day is used in schizophrenia and in the prevention of manic episodes, and 15 mg per day in the treatment of manic episodes, unless it is used with other medicines, in which case the starting dose can be 10 mg per day. The dose is adjusted according to how well the patient responds to and tolerates the treatment. The usual dose range is between 5 and 20 mg per day. The orodispersible tablets are taken by being placed on the tongue, where they disintegrate quickly in the saliva, or by mixing them in water before swallowing. Patients over 65 years of age and patients who have reduced liver or kidney function may need a lower starting dose of 5 mg per day.

## How does Zyprexa Velotab work?

The active substance in Zyprexa Velotab, olanzapine, is an antipsychotic medicine. It is known as an 'atypical' antipsychotic because it is different from the older antipsychotic medicines that have been available since the 1950s. Its exact mechanism of action is unknown, but it attaches to several different receptors on the surface of nerve cells in the brain. This disrupts signals transmitted between brain cells by 'neurotransmitters', chemicals that allow nerve cells to communicate with each other. It is thought that olanzapine's beneficial effect is due to it blocking receptors for the neurotransmitters 5?hydroxytrypamine (also called serotonin) and dopamine. Since these neurotransmitters are involved in schizophrenia and in bipolar disorder, olanzapine helps to normalise the activity of the brain, reducing the symptoms of these diseases.

## How has Zyprexa Velotab been studied?

Zyprexa Velotab contains the same active substance as another medicine called Zyprexa that has been authorised in the European Union (EU) since 1996. Because of this, the studies done with Zyprexa were used to support the use of Zyprexa Velotab. Three studies were also carried to show that, when taken by mouth, the two medicines produce equivalent levels of olanzapine in the blood.

## What benefit has Zyprexa Velotab shown during the studies?

Like Zyprexa, Zyprexa Velotab was more effective at improving symptoms than placebo (a dummy treatment). Zyprexa Velotab was as effective as the medicines that it was compared with for the treatment of adults with schizophrenia, the treatment of moderate to severe manic episodes in adults, and the prevention of recurrence in adults with bipolar disorder.

## What is the risk associated with Zyprexa Velotab?

The most common side effects with Zyprexa Velotab (seen in more than 1 patient in 10) are somnolence (sleepiness), weight gain, orthostatic hypotension (sudden drop in blood pressure on standing up) and raised levels of prolactin (a hormone). For the full list of all side effects reported with Zyprexa Velotab, see the package leaflet.

Zyprexa Velotab must not be used in people who are hypersensitive (allergic) to olanzapine or any of the other ingredients. It must also not be used in patients at risk of narrow-angle glaucoma (raised pressure inside the eye).

## Why has Zyprexa Velotab been approved?

The CHMP decided that Zyprexa Velotab's benefits are greater than its risks and recommended that Zyprexa Velotab be given marketing authorisation.

## Other information about Zyprexa Velotab

The European Commission granted a marketing authorisation valid throughout the European Union for Zyprexa Velotab on 3 February 2000.

For more information about treatment with Zyprexa Velotab, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Zyprexa Velotab : EPAR - Summary for the public

English (EN) (53.02 KB - PDF)

**First published:** 12/06/2009

**Last updated:** 03/07/2013

[View](/en/documents/overview/zyprexa-velotab-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-362)

български (BG) (135.25 KB - PDF)

**First published:**

12/06/2009

**Last updated:**

03/07/2013

[View](/bg/documents/overview/zyprexa-velotab-epar-summary-public_bg.pdf)

español (ES) (132.75 KB - PDF)

**First published:**

12/06/2009

**Last updated:**

03/07/2013

[View](/es/documents/overview/zyprexa-velotab-epar-summary-public_es.pdf)

čeština (CS) (125.25 KB - PDF)

**First published:**

12/06/2009

**Last updated:**

03/07/2013

[View](/cs/documents/overview/zyprexa-velotab-epar-summary-public_cs.pdf)

dansk (DA) (121.54 KB - PDF)

**First published:**

12/06/2009

**Last updated:**

03/07/2013

[View](/da/documents/overview/zyprexa-velotab-epar-summary-public_da.pdf)

Deutsch (DE) (133.01 KB - PDF)

**First published:**

12/06/2009

**Last updated:**

03/07/2013

[View](/de/documents/overview/zyprexa-velotab-epar-summary-public_de.pdf)

eesti keel (ET) (125.06 KB - PDF)

**First published:**

12/06/2009

**Last updated:**

03/07/2013

[View](/et/documents/overview/zyprexa-velotab-epar-summary-public_et.pdf)

ελληνικά (EL) (141.94 KB - PDF)

**First published:**

12/06/2009

**Last updated:**

03/07/2013

[View](/el/documents/overview/zyprexa-velotab-epar-summary-public_el.pdf)

français (FR) (123.92 KB - PDF)

**First published:**

12/06/2009

**Last updated:**

03/07/2013

[View](/fr/documents/overview/zyprexa-velotab-epar-summary-public_fr.pdf)

italiano (IT) (131.61 KB - PDF)

**First published:**

12/06/2009

**Last updated:**

03/07/2013

[View](/it/documents/overview/zyprexa-velotab-epar-summary-public_it.pdf)

latviešu valoda (LV) (136.23 KB - PDF)

**First published:**

12/06/2009

**Last updated:**

03/07/2013

[View](/lv/documents/overview/zyprexa-velotab-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (121.45 KB - PDF)

**First published:**

12/06/2009

**Last updated:**

03/07/2013

[View](/lt/documents/overview/zyprexa-velotab-epar-summary-public_lt.pdf)

magyar (HU) (134.84 KB - PDF)

**First published:**

12/06/2009

**Last updated:**

03/07/2013

[View](/hu/documents/overview/zyprexa-velotab-epar-summary-public_hu.pdf)

Malti (MT) (145.49 KB - PDF)

**First published:**

12/06/2009

**Last updated:**

03/07/2013

[View](/mt/documents/overview/zyprexa-velotab-epar-summary-public_mt.pdf)

Nederlands (NL) (121.32 KB - PDF)

**First published:**

12/06/2009

**Last updated:**

03/07/2013

[View](/nl/documents/overview/zyprexa-velotab-epar-summary-public_nl.pdf)

polski (PL) (134.33 KB - PDF)

**First published:**

12/06/2009

**Last updated:**

03/07/2013

[View](/pl/documents/overview/zyprexa-velotab-epar-summary-public_pl.pdf)

português (PT) (133.34 KB - PDF)

**First published:**

12/06/2009

**Last updated:**

03/07/2013

[View](/pt/documents/overview/zyprexa-velotab-epar-summary-public_pt.pdf)

română (RO) (131.87 KB - PDF)

**First published:**

12/06/2009

**Last updated:**

03/07/2013

[View](/ro/documents/overview/zyprexa-velotab-epar-summary-public_ro.pdf)

slovenčina (SK) (100.4 KB - PDF)

**First published:**

12/06/2009

**Last updated:**

03/07/2013

[View](/sk/documents/overview/zyprexa-velotab-epar-summary-public_sk.pdf)

slovenščina (SL) (131.76 KB - PDF)

**First published:**

12/06/2009

**Last updated:**

03/07/2013

[View](/sl/documents/overview/zyprexa-velotab-epar-summary-public_sl.pdf)

Suomi (FI) (120.16 KB - PDF)

**First published:**

12/06/2009

**Last updated:**

03/07/2013

[View](/fi/documents/overview/zyprexa-velotab-epar-summary-public_fi.pdf)

svenska (SV) (138.34 KB - PDF)

**First published:**

12/06/2009

**Last updated:**

03/07/2013

[View](/sv/documents/overview/zyprexa-velotab-epar-summary-public_sv.pdf)

## Product information

Zyprexa Velotab : EPAR - Product Information

English (EN) (460.74 KB - PDF)

**First published:** 20/08/2009

**Last updated:** 18/12/2024

[View](/en/documents/product-information/zyprexa-velotab-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-558)

български (BG) (569.62 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

18/12/2024

[View](/bg/documents/product-information/zyprexa-velotab-epar-product-information_bg.pdf)

español (ES) (446.88 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

18/12/2024

[View](/es/documents/product-information/zyprexa-velotab-epar-product-information_es.pdf)

čeština (CS) (480.79 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

18/12/2024

[View](/cs/documents/product-information/zyprexa-velotab-epar-product-information_cs.pdf)

dansk (DA) (463.71 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

18/12/2024

[View](/da/documents/product-information/zyprexa-velotab-epar-product-information_da.pdf)

Deutsch (DE) (444.77 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

18/12/2024

[View](/de/documents/product-information/zyprexa-velotab-epar-product-information_de.pdf)

eesti keel (ET) (450.81 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

18/12/2024

[View](/et/documents/product-information/zyprexa-velotab-epar-product-information_et.pdf)

ελληνικά (EL) (585.86 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

18/12/2024

[View](/el/documents/product-information/zyprexa-velotab-epar-product-information_el.pdf)

français (FR) (463.65 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

18/12/2024

[View](/fr/documents/product-information/zyprexa-velotab-epar-product-information_fr.pdf)

hrvatski (HR) (497.44 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

18/12/2024

[View](/hr/documents/product-information/zyprexa-velotab-epar-product-information_hr.pdf)

íslenska (IS) (416.43 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

18/12/2024

[View](/is/documents/product-information/zyprexa-velotab-epar-product-information_is.pdf)

italiano (IT) (441.26 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

18/12/2024

[View](/it/documents/product-information/zyprexa-velotab-epar-product-information_it.pdf)

latviešu valoda (LV) (519.11 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

18/12/2024

[View](/lv/documents/product-information/zyprexa-velotab-epar-product-information_lv.pdf)

lietuvių kalba (LT) (495.86 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

18/12/2024

[View](/lt/documents/product-information/zyprexa-velotab-epar-product-information_lt.pdf)

magyar (HU) (532.02 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

18/12/2024

[View](/hu/documents/product-information/zyprexa-velotab-epar-product-information_hu.pdf)

Malti (MT) (549.23 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

18/12/2024

[View](/mt/documents/product-information/zyprexa-velotab-epar-product-information_mt.pdf)

Nederlands (NL) (426.88 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

18/12/2024

[View](/nl/documents/product-information/zyprexa-velotab-epar-product-information_nl.pdf)

norsk (NO) (453.63 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

18/12/2024

[View](/no/documents/product-information/zyprexa-velotab-epar-product-information_no.pdf)

polski (PL) (510.14 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

18/12/2024

[View](/pl/documents/product-information/zyprexa-velotab-epar-product-information_pl.pdf)

português (PT) (462.5 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

18/12/2024

[View](/pt/documents/product-information/zyprexa-velotab-epar-product-information_pt.pdf)

română (RO) (512.8 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

18/12/2024

[View](/ro/documents/product-information/zyprexa-velotab-epar-product-information_ro.pdf)

slovenčina (SK) (525.48 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

18/12/2024

[View](/sk/documents/product-information/zyprexa-velotab-epar-product-information_sk.pdf)

slovenščina (SL) (523.86 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

18/12/2024

[View](/sl/documents/product-information/zyprexa-velotab-epar-product-information_sl.pdf)

Suomi (FI) (496.48 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

18/12/2024

[View](/fi/documents/product-information/zyprexa-velotab-epar-product-information_fi.pdf)

svenska (SV) (437.96 KB - PDF)

**First published:**

20/08/2009

**Last updated:**

18/12/2024

[View](/sv/documents/product-information/zyprexa-velotab-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IAIN/0103/G 16/12/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Zyprexa Velotab : EPAR - All Authorised presentations

English (EN) (22.21 KB - PDF)

**First published:** 03/05/2007

**Last updated:** 11/05/2016

[View](/en/documents/all-authorised-presentations/zyprexa-velotab-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-340)

български (BG) (56.49 KB - PDF)

**First published:**

03/05/2007

**Last updated:**

11/05/2016

[View](/bg/documents/all-authorised-presentations/zyprexa-velotab-epar-all-authorised-presentations_bg.pdf)

español (ES) (39.42 KB - PDF)

**First published:**

03/05/2007

**Last updated:**

11/05/2016

[View](/es/documents/all-authorised-presentations/zyprexa-velotab-epar-all-authorised-presentations_es.pdf)

čeština (CS) (27.87 KB - PDF)

**First published:**

03/05/2007

**Last updated:**

11/05/2016

[View](/cs/documents/all-authorised-presentations/zyprexa-velotab-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (19.12 KB - PDF)

**First published:**

03/05/2007

**Last updated:**

11/05/2016

[View](/da/documents/all-authorised-presentations/zyprexa-velotab-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (18.91 KB - PDF)

**First published:**

03/05/2007

**Last updated:**

11/05/2016

[View](/de/documents/all-authorised-presentations/zyprexa-velotab-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (19.9 KB - PDF)

**First published:**

03/05/2007

**Last updated:**

11/05/2016

[View](/et/documents/all-authorised-presentations/zyprexa-velotab-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (43.23 KB - PDF)

**First published:**

03/05/2007

**Last updated:**

11/05/2016

[View](/el/documents/all-authorised-presentations/zyprexa-velotab-epar-all-authorised-presentations_el.pdf)

français (FR) (38.92 KB - PDF)

**First published:**

03/05/2007

**Last updated:**

11/05/2016

[View](/fr/documents/all-authorised-presentations/zyprexa-velotab-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (29.45 KB - PDF)

**First published:**

03/05/2007

**Last updated:**

11/05/2016

[View](/hr/documents/all-authorised-presentations/zyprexa-velotab-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (19.02 KB - PDF)

**First published:**

03/05/2007

**Last updated:**

11/05/2016

[View](/is/documents/all-authorised-presentations/zyprexa-velotab-epar-all-authorised-presentations_is.pdf)

italiano (IT) (21.48 KB - PDF)

**First published:**

03/05/2007

**Last updated:**

11/05/2016

[View](/it/documents/all-authorised-presentations/zyprexa-velotab-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (39.86 KB - PDF)

**First published:**

03/05/2007

**Last updated:**

11/05/2016

[View](/lv/documents/all-authorised-presentations/zyprexa-velotab-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (42.61 KB - PDF)

**First published:**

03/05/2007

**Last updated:**

11/05/2016

[View](/lt/documents/all-authorised-presentations/zyprexa-velotab-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (29.39 KB - PDF)

**First published:**

03/05/2007

**Last updated:**

11/05/2016

[View](/hu/documents/all-authorised-presentations/zyprexa-velotab-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (38.31 KB - PDF)

**First published:**

03/05/2007

**Last updated:**

11/05/2016

[View](/mt/documents/all-authorised-presentations/zyprexa-velotab-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (20.35 KB - PDF)

**First published:**

03/05/2007

**Last updated:**

11/05/2016

[View](/nl/documents/all-authorised-presentations/zyprexa-velotab-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (19.25 KB - PDF)

**First published:**

03/05/2007

**Last updated:**

11/05/2016

[View](/no/documents/all-authorised-presentations/zyprexa-velotab-epar-all-authorised-presentations_no.pdf)

polski (PL) (39.29 KB - PDF)

**First published:**

03/05/2007

**Last updated:**

11/05/2016

[View](/pl/documents/all-authorised-presentations/zyprexa-velotab-epar-all-authorised-presentations_pl.pdf)

português (PT) (21.96 KB - PDF)

**First published:**

03/05/2007

**Last updated:**

11/05/2016

[View](/pt/documents/all-authorised-presentations/zyprexa-velotab-epar-all-authorised-presentations_pt.pdf)

română (RO) (37.08 KB - PDF)

**First published:**

03/05/2007

**Last updated:**

11/05/2016

[View](/ro/documents/all-authorised-presentations/zyprexa-velotab-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (29.95 KB - PDF)

**First published:**

03/05/2007

**Last updated:**

11/05/2016

[View](/sk/documents/all-authorised-presentations/zyprexa-velotab-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (47.7 KB - PDF)

**First published:**

03/05/2007

**Last updated:**

11/05/2016

[View](/sl/documents/all-authorised-presentations/zyprexa-velotab-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (66.59 KB - PDF)

**First published:**

03/05/2007

**Last updated:**

11/05/2016

[View](/fi/documents/all-authorised-presentations/zyprexa-velotab-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (18.76 KB - PDF)

**First published:**

03/05/2007

**Last updated:**

11/05/2016

[View](/sv/documents/all-authorised-presentations/zyprexa-velotab-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Zyprexa Velotab Active substance olanzapine International non-proprietary name (INN) or common name olanzapine Therapeutic area (MeSH)

- Schizophrenia
- Bipolar Disorder

Anatomical therapeutic chemical (ATC) code N05AH03

### Pharmacotherapeutic group

Psycholeptics

### Therapeutic indication

**Adults**

Olanzapine is indicated for the treatment of schizophrenia.

Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.

Olanzapine is indicated for the treatment of moderate to severe manic episode.

In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.

## Authorisation details

EMA product number EMEA/H/C/000287 Marketing authorisation holder

CHEPLAPHARM Registration GmbH

Weilerstr. 5e

Opinion adopted 21/10/1999 Marketing authorisation issued 03/02/2000 Revision 34

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Zyprexa Velotab : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (236.89 KB - PDF)

**First published:** 20/08/2009

**Last updated:** 18/12/2024

[View](/en/documents/procedural-steps-after/zyprexa-velotab-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Zyprexa Velotab-H-C-PSUSA-00010540-201903 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/132332/2020

English (EN) (166.29 KB - PDF)

**First published:** 12/03/2020

[View](/en/documents/scientific-conclusion/zyprexa-velotab-h-c-psusa-00010540-201903-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Zyprexa Velotab-H-C-287-WS-485 : EPAR - Assessment Report

Adopted

Reference Number: EMA/334375/2014

English (EN) (535.71 KB - PDF)

**First published:** 26/06/2014

**Last updated:** 26/06/2014

[View](/en/documents/variation-report/zyprexa-velotab-h-c-287-ws-485-epar-assessment-report_en.pdf)

Zyprexa Velotab-H-C-287-P45-30 : EPAR - Assessment Report

Adopted

Reference Number: EMA/640279/2012

English (EN) (65.09 KB - PDF)

**First published:** 11/10/2012

**Last updated:** 11/10/2012

[View](/en/documents/variation-report/zyprexa-velotab-h-c-287-p45-30-epar-assessment-report_en.pdf)

Zyprexa Velotab : EPAR - Steps taken after authorisation when a cutoff date has been used

English (EN) (101.24 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 21/10/2005

[View](/en/documents/steps-after-cutoff/zyprexa-velotab-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf)

## Initial marketing authorisation documents

Zyprexa Velotab : EPAR - Procedural steps taken before authorisation

English (EN) (99.53 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 21/10/2005

[View](/en/documents/procedural-steps/zyprexa-velotab-epar-procedural-steps-taken-authorisation_en.pdf)

Zyprexa Velotab : EPAR - Scientific Discussion

English (EN) (296.91 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 21/10/2005

[View](/en/documents/scientific-discussion/zyprexa-velotab-epar-scientific-discussion_en.pdf)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 18/12/2024

## Share this page

[Back to top](#main-content)